On the contrary, Musil et al. examined MDD patients during five weeks of reboxetine and add-on celecoxib or placebo treatment and reported no significant MIF change between inclusion and study endpoint, and also no association between MIF course and HAM-D course [29]. This evidence concerns the gene MIF and major depressive disorder.